Stamford, Connecticut, United States Thomas, McNerney & Partners appeared to be the VC, which was created in 2003. The venture was found in North America in United States. The leading representative office of defined VC is situated in the Stamford.
The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Thomas, McNerney & Partners, startups are often financed by Sanderling Ventures, Versant Ventures, Techno Venture Management. The meaningful sponsors for the fund in investment in the same round are Investor Growth Capital Limited, H.I.G. Capital, Sanderling Ventures. In the next rounds fund is usually obtained by Investor Growth Capital Limited, Accuitive Medical Ventures, Versant Ventures.
This organization was formed by Karen Boezi, Peter H. McNerney. Besides them, we counted 1 critical employee of this fund in our database.
Among the most popular portfolio startups of the fund, we may highlight Auspex Pharmaceuticals, Celator Pharmaceuticals, Elron Electronic Industries. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has specific favorite in a number of founders of portfolio startups. In case when startup counts 3 or 4 of the founder, the chance for it to get the investment is meager. Among the most successful fund investment fields, there are Therapeutics, Biopharma.
The fund is constantly included in 2-6 investment rounds annually. The usual things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2010. This Thomas, McNerney & Partners works on 4 percentage points more the average amount of lead investments comparing to the other organizations. The increased amount of exits for fund were in 2010. Speaking about the real fund results, this VC is 15 percentage points more often commits exit comparing to other organizations.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Alliansys-Nord Creation | Eurville, France, Haute-Normandie |
| Alpha Fund | - |
| Bailibowen | Beijing, Beijing, China |
| Brazil Warrant | Brazil, São Paulo, Sao Paulo |
| Brio Ventures | British Columbia, Canada, Vernon |
| BW Ventures | Eindhoven, Noord-Brabant, The Netherlands |
| Company X Media | New York, New York, United States |
| Emergent Technology Holdings | Houston, Texas, United States |
| Equator Capital Partners | Chicago, Illinois, United States |
| Falcon Angel Investor | Beijing, Beijing, China |
| Goldcrest Investments | Dallas, Texas, United States |
| J.L. Albright Venture Partners | - |
| Lean FUND | Belgium, Louvain, Vlaams-Brabant |
| Namier Capital Partners | England, London, United Kingdom |
| Salvesen & Thams | Norway, South Carolina, United States |
| Shenzhen Lanhai Zhongli Capital Management | China, Guangdong, Shenzhen |
| Translunar One | Austin, Texas, United States |
| UOB Investment | Beijing, China, Haidian |
| Wentianxia Investment | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
SG Biofuels | $11M | 09 Sep 2014 | California, United States | ||
Cebix | $33M | 18 Oct 2012 | San Diego, California, United States | ||
Tioga Pharmaceuticals | $10M | 12 Apr 2012 | San Diego, California, United States | ||
| $17M | 17 Jan 2012 | California, United States | |||
InnoPharma | $15M | 02 Dec 2011 | New Jersey, United States | ||
Auspex Pharmaceuticals | $12M | 13 Oct 2010 | - | ||
NeuroTherapeutics Pharma | $43M | 20 May 2010 | Chicago, Illinois, United States | ||
Altair Therapeutics | $17M | 02 Feb 2010 | San Diego, California, United States | ||
Virdante Pharmaceuticals | $30M | 25 Nov 2009 | Cambridge, Massachusetts, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
SG Biofuels | $11M | 09 Sep 2014 | California, United States | ||
Cebix | $33M | 18 Oct 2012 | San Diego, California, United States | ||
Tioga Pharmaceuticals | $10M | 12 Apr 2012 | San Diego, California, United States | ||
| $17M | 17 Jan 2012 | California, United States | |||
InnoPharma | $15M | 02 Dec 2011 | New Jersey, United States | ||
Auspex Pharmaceuticals | $12M | 13 Oct 2010 | - | ||
NeuroTherapeutics Pharma | $43M | 20 May 2010 | Chicago, Illinois, United States | ||
Altair Therapeutics | $17M | 02 Feb 2010 | San Diego, California, United States | ||
Virdante Pharmaceuticals | $30M | 25 Nov 2009 | Cambridge, Massachusetts, United States |
